Skip to main content

Some NLM-NCBI services and products are experiencing heavy traffic, which may affect performance and availability. We apologize for the inconvenience and appreciate your patience. For assistance, please contact our Help Desk at info@ncbi.nlm.nih.gov.

Infection and Immunity logoLink to Infection and Immunity
. 1996 Jun;64(6):2220–2224. doi: 10.1128/iai.64.6.2220-2224.1996

Preclinical immunoprophylactic and immunotherapeutic efficacy of antisera to capsular polysaccharide-tetanus toxoid conjugate vaccines of Vibrio vulnificus.

S J Devi 1, U Hayat 1, J L Powell 1, J G Morris Jr 1
PMCID: PMC174059  PMID: 8675330

Abstract

Vibrio vulnificus is an oyster-associated bacterial pathogen that causes life-threatening fulminating septicemia and necrotizing wound infections in humans. The capsular polysaccharide of V. vulnificus (VvPS) is critical for virulence. Previously we showed that active immunization of mice with a VvPS-tetanus toxoid (VvPS-TTa) conjugate vaccine conferred significantly higher protection against subsequent lethal challenge than immunization with VvPS alone. In the current study, we examined the utility of immunoprophylaxis or immunotherapy with hyperimmune antisera elicited by VvPS-TTa and VvPS-TTb conjugate vaccines prepared by different synthetic schemes. First we demonstrated that the Ribi adjuvant significantly enhanced the murine antibody response (P < or = 0.02) to both conjugates. Subsequently, high-titered polyclonal antisera were raised to VvPS-TTa and VvPS-TTb conjugate vaccines by using Ribi adjuvant or Freund's adjuvants. Antisera were observed to have protective effects when administered before and after acute lethal infection. All animals receiving prophylactic antisera intraperitoneally 24 h before lethal challenge with homologous carbotype 1 were protected, while 73 to 100% of control mice succumbed. Immunotherapy was also effective, with survival rates of 60 to 73% seen among mice when antisera were administered 2 h after bacterial challenge, at a time when symptoms of infection were already apparent. The protective effect of capsular antiserum appeared to be serotype specific. Antisera to the, carbotype 1 VvPS-TTa vaccine did not confer cross-protection against lethal challenge with carbotype 2 V. vulnificus despite partial structural similarity and a weak serological cross-reaction between the two carbotypes. Immune globulins induced by a potential multivalent VvPS conjugate vaccine composed of clinically prevalent carbotypes may have utility in the management of V. vulnificus infections and deserve further evaluation.

Full Text

The Full Text of this article is available as a PDF (256.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bahrani K., Oliver J. D. Studies on the lipopolysaccharide of a virulent and an avirulent strain of Vibrio vulnificus. Biochem Cell Biol. 1990 Feb;68(2):547–551. doi: 10.1139/o90-078. [DOI] [PubMed] [Google Scholar]
  2. Carruthers M. M., Kabat W. J. Vibrio vulnificus (lactose-positive vibrio) and Vibrio parahaemolyticus differ in their susceptibilities to human serum. Infect Immun. 1981 May;32(2):964–966. doi: 10.1128/iai.32.2.964-966.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Chin K. P., Lowe M. A., Tong M. J., Koehler A. L. Vibrio vulnificus infection after raw oyster ingestion in a patient with liver disease and acquired immune deficiency syndrome-related complex. Gastroenterology. 1987 Mar;92(3):796–799. doi: 10.1016/0016-5085(87)90035-7. [DOI] [PubMed] [Google Scholar]
  4. Chuang Y. C., Yuan C. Y., Liu C. Y., Lan C. K., Huang A. H. Vibrio vulnificus infection in Taiwan: report of 28 cases and review of clinical manifestations and treatment. Clin Infect Dis. 1992 Aug;15(2):271–276. doi: 10.1093/clinids/15.2.271. [DOI] [PubMed] [Google Scholar]
  5. Devi S. J., Hayat U., Frasch C. E., Kreger A. S., Morris J. G., Jr Capsular polysaccharide-protein conjugate vaccines of carbotype 1 Vibrio vulnificus: construction, immunogenicity, and protective efficacy in a murine model. Infect Immun. 1995 Aug;63(8):2906–2911. doi: 10.1128/iai.63.8.2906-2911.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Gray L. D., Kreger A. S. Mouse skin damage caused by cytolysin from Vibrio vulnificus and by V. vulnificus infection. J Infect Dis. 1987 Feb;155(2):236–241. doi: 10.1093/infdis/155.2.236. [DOI] [PubMed] [Google Scholar]
  7. Hayat U., Reddy G. P., Bush C. A., Johnson J. A., Wright A. C., Morris J. G., Jr Capsular types of Vibrio vulnificus: an analysis of strains from clinical and environmental sources. J Infect Dis. 1993 Sep;168(3):758–762. doi: 10.1093/infdis/168.3.758. [DOI] [PubMed] [Google Scholar]
  8. Hoge C. W., Watsky D., Peeler R. N., Libonati J. P., Israel E., Morris J. G., Jr Epidemiology and spectrum of Vibrio infections in a Chesapeake Bay community. J Infect Dis. 1989 Dec;160(6):985–993. doi: 10.1093/infdis/160.6.985. [DOI] [PubMed] [Google Scholar]
  9. Johnson D. E., Calia F. M., Musher D. M., Goree A. Resistance of Vibrio vulnificus to serum bactericidal and opsonizing factors: relation to virulence in suckling mice and humans. J Infect Dis. 1984 Sep;150(3):413–418. doi: 10.1093/infdis/150.3.413. [DOI] [PubMed] [Google Scholar]
  10. Johnston J. M., Becker S. F., McFarland L. M. Vibrio vulnificus. Man and the sea. JAMA. 1985 May 17;253(19):2850–2853. doi: 10.1001/jama.253.19.2850. [DOI] [PubMed] [Google Scholar]
  11. Kikawa K., Yamasaki K., Sujiura T., Myose H., Chinen M., Tsutsumi K., Iwao N., Dohzono T. A successfully treated case of Vibrio vulnificus septicemia with shock. Jpn J Med. 1990 May-Jun;29(3):313–319. doi: 10.2169/internalmedicine1962.29.313. [DOI] [PubMed] [Google Scholar]
  12. Klontz K. C., Lieb S., Schreiber M., Janowski H. T., Baldy L. M., Gunn R. A. Syndromes of Vibrio vulnificus infections. Clinical and epidemiologic features in Florida cases, 1981-1987. Ann Intern Med. 1988 Aug 15;109(4):318–323. doi: 10.7326/0003-4819-109-4-318. [DOI] [PubMed] [Google Scholar]
  13. Koenig K. L., Mueller J., Rose T. Vibrio vulnificus. Hazard on the half shell. West J Med. 1991 Oct;155(4):400–403. [PMC free article] [PubMed] [Google Scholar]
  14. Kothary M. H., Kreger A. S. Production and partial characterization of an elastolytic protease of Vibrio vulnificus. Infect Immun. 1985 Nov;50(2):534–540. doi: 10.1128/iai.50.2.534-540.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kreger A. S., Gray L. D., Testa J. Protection of mice against Vibrio vulnificus disease by vaccination with surface antigen preparations and anti-surface antigen antisera. Infect Immun. 1984 Sep;45(3):537–543. doi: 10.1128/iai.45.3.537-543.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Kreger A., DeChatelet L., Shirley P. Interaction of Vibrio vulnificus with human polymorphonuclear leukocytes: association of virulence with resistance to phagocytosis. J Infect Dis. 1981 Sep;144(3):244–248. doi: 10.1093/infdis/144.3.244. [DOI] [PubMed] [Google Scholar]
  17. Mitchell M. S., Kan-Mitchell J., Kempf R. A., Harel W., Shau H. Y., Lind S. Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res. 1988 Oct 15;48(20):5883–5893. [PubMed] [Google Scholar]
  18. Morris J. G., Jr Vibrio vulnificus--a new monster of the deep? Ann Intern Med. 1988 Aug 15;109(4):261–263. doi: 10.7326/0003-4819-109-4-261. [DOI] [PubMed] [Google Scholar]
  19. Park S. D., Shon H. S., Joh N. J. Vibrio vulnificus septicemia in Korea: clinical and epidemiologic findings in seventy patients. J Am Acad Dermatol. 1991 Mar;24(3):397–403. doi: 10.1016/0190-9622(91)70059-b. [DOI] [PubMed] [Google Scholar]
  20. Pennington J. E. Newer uses of intravenous immunoglobulins as anti-infective agents. Antimicrob Agents Chemother. 1990 Aug;34(8):1463–1466. doi: 10.1128/aac.34.8.1463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Reddy G. P., Hayat U., Abeygunawardana C., Fox C., Wright A. C., Maneval D. R., Jr, Bush C. A., Morris J. G., Jr Purification and determination of the structure of capsular polysaccharide of Vibrio vulnificus M06-24. J Bacteriol. 1992 Apr;174(8):2620–2630. doi: 10.1128/jb.174.8.2620-2630.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Reddy G. P., Hayat U., Bush C. A., Morris J. G., Jr Capsular polysaccharide structure of a clinical isolate of Vibrio vulnificus strain BO62316 determined by heteronuclear NMR spectroscopy and high-performance anion-exchange chromatography. Anal Biochem. 1993 Oct;214(1):106–115. doi: 10.1006/abio.1993.1463. [DOI] [PubMed] [Google Scholar]
  23. Rickman L. S., Gordon D. M., Wistar R., Jr, Krzych U., Gross M., Hollingdale M. R., Egan J. E., Chulay J. D., Hoffman S. L. Use of adjuvant containing mycobacterial cell-wall skeleton, monophosphoryl lipid A, and squalane in malaria circumsporozoite protein vaccine. Lancet. 1991 Apr 27;337(8748):998–1001. doi: 10.1016/0140-6736(91)92659-p. [DOI] [PubMed] [Google Scholar]
  24. Shinoda S., Kobayashi M., Yamada H., Yoshida S., Ogawa M., Mizuguchi Y. Inhibitory effect of capsular antigen of Vibrio vulnificus on bactericidal activity of human serum. Microbiol Immunol. 1987;31(5):393–401. doi: 10.1111/j.1348-0421.1987.tb03102.x. [DOI] [PubMed] [Google Scholar]
  25. Siber G. R., Ambrosino D. M., McIver J., Ervin T. J., Schiffman G., Sallan S., Grady G. F. Preparation of human hyperimmune globulin to Haemophilus influenzae b, Streptococcus pneumoniae, and Neisseria meningitidis. Infect Immun. 1984 Jul;45(1):248–254. doi: 10.1128/iai.45.1.248-254.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Simpson L. M., White V. K., Zane S. F., Oliver J. D. Correlation between virulence and colony morphology in Vibrio vulnificus. Infect Immun. 1987 Jan;55(1):269–272. doi: 10.1128/iai.55.1.269-272.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Tacket C. O., Brenner F., Blake P. A. Clinical features and an epidemiological study of Vibrio vulnificus infections. J Infect Dis. 1984 Apr;149(4):558–561. doi: 10.1093/infdis/149.4.558. [DOI] [PubMed] [Google Scholar]
  28. Takayama K., Qureshi N., Ribi E., Cantrell J. L. Separation and characterization of toxic and nontoxic forms of lipid A. Rev Infect Dis. 1984 Jul-Aug;6(4):439–443. doi: 10.1093/clinids/6.4.439. [DOI] [PubMed] [Google Scholar]
  29. Wright A. C., Morris J. G., Jr The extracellular cytolysin of Vibrio vulnificus: inactivation and relationship to virulence in mice. Infect Immun. 1991 Jan;59(1):192–197. doi: 10.1128/iai.59.1.192-197.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Wright A. C., Simpson L. M., Oliver J. D., Morris J. G., Jr Phenotypic evaluation of acapsular transposon mutants of Vibrio vulnificus. Infect Immun. 1990 Jun;58(6):1769–1773. doi: 10.1128/iai.58.6.1769-1773.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Yoshida S., Ogawa M., Mizuguchi Y. Relation of capsular materials and colony opacity to virulence of Vibrio vulnificus. Infect Immun. 1985 Feb;47(2):446–451. doi: 10.1128/iai.47.2.446-451.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES